NORTHERN TRUST CORP - ONCOCYTE CORP ownership

ONCOCYTE CORP's ticker is OCX and the CUSIP is 68235C107. A total of 61 filers reported holding ONCOCYTE CORP in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
NORTHERN TRUST CORP ownership history of ONCOCYTE CORP
ValueSharesWeighting
Q2 2023$44,829
-35.1%
194,9110.0%0.00%
Q1 2023$69,077
+3.1%
194,911
-6.7%
0.00%
Q4 2022$67,003
-55.9%
208,7990.0%0.00%
Q3 2022$152,000
-19.1%
208,7990.0%0.00%
Q2 2022$188,000
-77.1%
208,799
-62.2%
0.00%
Q1 2022$822,000
-35.0%
551,909
-5.3%
0.00%
Q4 2021$1,264,000
-40.3%
582,542
-2.1%
0.00%
Q3 2021$2,118,000
-54.6%
594,929
-26.8%
0.00%
-100.0%
Q2 2021$4,667,000
+21.1%
812,896
+9.5%
0.00%0.0%
Q1 2021$3,853,000
+137.5%
742,362
+9.4%
0.00%
Q4 2020$1,622,000
+75.2%
678,620
+1.9%
0.00%
Q3 2020$926,000
-1.9%
665,869
+34.8%
0.00%
Q2 2020$944,000
+30.6%
494,032
+67.5%
0.00%
Q1 2020$723,000
+27.1%
294,970
+16.6%
0.00%
Q4 2019$569,000
+8.6%
253,054
+1.3%
0.00%
Q3 2019$524,000
+184.8%
249,685
+237.5%
0.00%
Q2 2019$184,000
-16.4%
73,973
+32.4%
0.00%
Q1 2019$220,000
+1000.0%
55,873
+275.6%
0.00%
Q4 2018$20,000
-45.9%
14,8770.0%0.00%
Q3 2018$37,000
+42.3%
14,877
+45.9%
0.00%
Q2 2018$26,000
-71.7%
10,197
-76.9%
0.00%
Q1 2018$92,000
-55.1%
44,064
+0.0%
0.00%
Q4 2017$205,000
-38.1%
44,048
+0.3%
0.00%
Q3 2017$331,000
+56.9%
43,920
+7.8%
0.00%
Q2 2017$211,000
+56.3%
40,732
+39.2%
0.00%
Q1 2016$135,00029,2510.00%
Other shareholders
ONCOCYTE CORP shareholders Q3 2020
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 17,349,945$61,766,0003.15%
Defender Capital, LLC. 1,960,820$6,935,0002.26%
Millrace Asset Group, Inc. 613,885$2,185,0001.36%
PURA VIDA INVESTMENTS, LLC 12,223,953$43,517,0001.32%
Penbrook Management LLC 577,200$2,055,0001.28%
ACT CAPITAL MANAGEMENT, LLC 330,000$1,175,0000.61%
AWM Investment Company, Inc. 717,000$2,553,0000.25%
Colonial River Wealth Management, LLC 66,200$218,0000.15%
CALIBER WEALTH MANAGEMENT, LLC 66,200$218,0000.15%
Fort Sheridan Advisors LLC 110,000$392,0000.13%
View complete list of ONCOCYTE CORP shareholders